title: Interventions for treating anxiety after stroke.
abstract: BACKGROUND
  Approximately 20% of stroke patients experience anxiety at some point after stroke.
  
  
  OBJECTIVE
  To determine if any treatment for anxiety after stroke decreases the proportion of patients with anxiety disorders or symptoms, and to determine the effect of treatment on quality of life, disability, depression, social participation, risk of death or caregiver burden.
  
  
  METHODS
  We searched the trials register of the Cochrane Stroke Group (October 2010), CENTRAL (The Cochrane Library 2010, Issue 4), MEDLINE (1950 to October 2010), EMBASE (1947 to October 2010), PsycINFO (1806 to October 2010), Allied and Complementary Medicine database (AMED) (1985 to October 2010), Cumulative Index to Nursing and Allied Health (CINAHL) (1982 to October 2010), Proquest Digital Dissertations (1861 to October 2010), and Psychological Database for Brain Impairment Treatment Efficacy (PsycBITE) (2004 to October 2010). In an effort to identify further published, unpublished and ongoing trials, we searched trial registries and major international stroke conference proceedings, scanned reference lists, and contacted select individuals known to the review team who are actively involved in psychological aspects of stroke research, and the Association of the British Pharmaceutical Industry.
  
  
  METHODS
  Two review authors independently screened and selected titles and abstracts for inclusion in the review. Randomised trials of any intervention in patients with stroke where the treatment of anxiety was an outcome were eligible.
  
  
  METHODS
  Two review authors independently extracted data for analysis. We performed a narrative review. A meta-analysis was planned but not carried out as studies were not of sufficient quality to warrant doing so.
  
  
  RESULTS
  We included two trials (three interventions) involving 175 participants with co-morbid anxiety and depression in the review. Both trials used the Hamilton Anxiety Scale (HAM-A) to assess anxiety, and neither included a placebo control group. One trial randomised 81 patients to paroxetine, paroxetine plus psychotherapy or standard care. Mean level of anxiety severity scores were 58% and 71% lower in the paroxetine, and paroxetine plus psychotherapy groups respectively compared with those in standard care at follow-up (P < 0.01). The second trial randomised 94 stroke patients, also with co-morbid anxiety and depression, to receive buspirone hydrochloride or standard care. At follow-up, the mean level of anxiety was significantly lower for those receiving buspirone relative to controls (P < 0.01). Half of the participants receiving paroxetine experienced adverse events that included nausea, vomiting or dizziness; however, only 14% of those receiving buspirone experienced nausea or palpitations. No information was provided about the duration of symptoms associated with adverse events.
  
  
  CONCLUSIONS
  There is insufficient evidence to guide the treatment of anxiety after stroke. The data available suggest that pharmaceutical therapy (paroxetine and buspirone) may be effective in reducing anxiety symptoms in stroke patients with co-morbid anxiety and depression. No information was available for stroke patients with anxiety only. Randomised placebo controlled trials are needed.
authors.affiliation: School of Healthcare, University of Leeds, Baines Wing Room 3.35, Leeds, UK, LS2 9JT.
authors.forename: C Alexia
authors.initials: CA
authors.lastname: Campbell Burton
authors.forename: John
authors.initials: J
authors.lastname: Holmes
authors.forename: Jenni
authors.initials: J
authors.lastname: Murray
authors.forename: David
authors.initials: D
authors.lastname: Gillespie
authors.forename: C Elizabeth
authors.initials: CE
authors.lastname: Lightbody
authors.forename: Caroline L
authors.initials: CL
authors.lastname: Watkins
authors.forename: Peter
authors.initials: P
authors.lastname: Knapp
mesh_terms: D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001007:Anxiety / Q000209:etiology / Q000628:therapy*; D002065:Buspirone / Q000627:therapeutic use; D006801:Humans; D017374:Paroxetine / Q000627:therapeutic use; D011613:Psychotherapy; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000523:psychology*
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D017374:Paroxetine; D002065:Buspirone